Columbia, Missouri 65212

  • AML, Adult

Purpose:

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimen from the blood and bone marrow will increase understanding of effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies.


Study summary:

Specific targets and novel strategies to eliminate AML stem cells are required for AML treatment. Collecting specimen from the blood and bone marrow will increase understanding of effect of DPP4 inhibitors on human AML-SCP to develop individualized therapies. We will test the effect of DPP4 inhibitors on human AML-SCP in vitro and in vivo and whether addition of DPP4 inhibitors can prevent AML relapse once the disease is in the remission stage.


Criteria:

Inclusion Criteria: - Acute myeloid leukemia patients, must be 18 or older. Exclusion Criteria: - 1) Participants with impaired decision-making capacities; 2) Pregnant women or fetuses ; 3) Children (under 18 in Missouri, also dependent on State law); 4) Non-viable neonates or neonates of uncertain viability (neonates=newborns); 5) Non-English speaking subjects; 6) Prisoners.


NCT ID:

NCT04841447


Primary Contact:

Xunlei Kang, MD.PhD
Phone: 5738844524
Email: kangxu@health.missouri.edu


Backup Contact:

Email: caomi@health.missouri.edu
Min Cao, MD
Phone: 5738844524


Location Contact:

Columbia, Missouri 65212
United States

Xunlei Kang, MD.PhD
Phone: 573-884-4524
Email: kangxu@health.missouri.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.